169 related articles for article (PubMed ID: 38196976)
1. Targeted Sensitization of Glioblastoma Multiforme Using AAAPT Technology.
Mendieta M; Avci NG; Pandurangi R; Akay YM; Akay M
IEEE Open J Eng Med Biol; 2023; 4():251-258. PubMed ID: 38196976
[TBL] [Abstract][Full Text] [Related]
2. A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment.
Pandurangi RS; Tomasetti M; Verapazham ST; Paulmurugan R; Ma C; Rajput S; Anjanappa M; Nakshatri H
PLoS One; 2021; 16(2):e0225869. PubMed ID: 33556062
[TBL] [Abstract][Full Text] [Related]
3. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway.
Tang Q; Cao H; Tong N; Liu Y; Wang W; Zou Y; Xu L; Zeng Z; Xu W; Yin Z; Ma W; Wang Q
Phytomedicine; 2022 May; 99():154016. PubMed ID: 35278900
[TBL] [Abstract][Full Text] [Related]
4. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV
Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
6. Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis.
Stillger MN; Chen CY; Lai ZW; Li M; Schäfer A; Pagenstecher A; Nimsky C; Bartsch JW; Schilling O
Cancer Cell Int; 2023 Mar; 23(1):49. PubMed ID: 36932402
[TBL] [Abstract][Full Text] [Related]
7. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
Zhao J; Yang S; Cui X; Wang Q; Yang E; Tong F; Hong B; Xiao M; Xin L; Xu C; Tan Y; Kang C
Neuro Oncol; 2023 May; 25(5):857-870. PubMed ID: 36272139
[TBL] [Abstract][Full Text] [Related]
8. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
[TBL] [Abstract][Full Text] [Related]
9. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
10. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
Zhao W; Yun K
Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776
[TBL] [Abstract][Full Text] [Related]
11. Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
Sun S; Lee D; Lee NP; Pu JK; Wong ST; Lui WM; Fung CF; Leung GK
J Neurooncol; 2012 Sep; 109(3):467-75. PubMed ID: 22763762
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide resistance in glioblastoma multiforme.
Lee SY
Genes Dis; 2016 Sep; 3(3):198-210. PubMed ID: 30258889
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Chiang IT; Liu YC; Liu HS; Ali AAA; Chou SY; Hsu TI; Hsu FT
Neurotherapeutics; 2022 Mar; 19(2):616-634. PubMed ID: 35267171
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
16. Autophagy inhibition potentiates SAHA‑mediated apoptosis in glioblastoma cells by accumulation of damaged mitochondria.
Lohitesh K; Saini H; Srivastava A; Mukherjee S; Roy A; Chowdhury R
Oncol Rep; 2018 Jun; 39(6):2787-2796. PubMed ID: 29658588
[TBL] [Abstract][Full Text] [Related]
17. Histone 2A Family Member J Drives Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Multiforme.
Lee HH; Lin CH; Lin HY; Kuei CH; Zheng JQ; Wang YH; Lu LS; Lee FP; Hu CJ; Wu D; Lin YF
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31906036
[TBL] [Abstract][Full Text] [Related]
18. Quercetin induces MGMT
Wang W; Yuan X; Mu J; Zou Y; Xu L; Chen J; Zhu X; Li B; Zeng Z; Wu X; Yin Z; Wang Q
Phytomedicine; 2023 Sep; 118():154933. PubMed ID: 37451151
[TBL] [Abstract][Full Text] [Related]
19. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
Yang B; Ma YB; Chu SH
Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
[TBL] [Abstract][Full Text] [Related]
20. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.
Zhang N; Wu X; Yang L; Xiao F; Zhang H; Zhou A; Huang Z; Huang S
Clin Cancer Res; 2012 Nov; 18(21):5961-71. PubMed ID: 22977194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
